Abstract
Background. Various forms of endometrioid disease affect 7–10% of women of reproductive age and are an important factor in reducing fertility and quality of life. The basis of modern comprehensive therapy is surgery and hormonal agents. Aim. To conduct a meta-analysis of the literature on using dienogest (Zafrilla) for treating pain in endometriosis. Materials and methods. The review and meta-analysis were conducted according to the guidelines of the Cochrane Society and in compliance with the recommendations for systematic reviews and meta-analyses. Data sources for the meta-analysis include publications in the PubMed database between 1997 and February 2024 and relevant research articles in Russian mentioning Zafrilla. Keywords such as "dienogest," "endometriosis surgery," "endometriosis treatment," and "endometriosis" were used to identify relevant studies. The main criterion for the primary assessment was pain relief; the additional one was endometrioma and/or pain recurrence, which indicated a disease relapse. For the meta-analysis, studies mentioning Zafrilla were selected. The study protocol is registered online in the International Prospective Registry of Systematic Reviews (CRD3034892022). Results. Based on the analyzed results of previously published studies, it was found that Zafrilla's effectiveness significantly exceeded placebo and (in some studies) was similar to that of the gonadotropin-releasing hormone agonist in reducing the severity and frequency of pain and relapse after surgery for infiltrative endometriosis and endometriomas. The weighted mean difference with the 95% confidence interval was 1.20 in reducing the pain severity and 1.17 in reducing the number of clinical and morphological relapses in endometriomas and infiltrative endometriosis. The magnitude of the effect for spontaneous pregnancy after surgery and/or endometriosis monotherapy with Zafrilla was 0.9 (relative risk with 95% confidence interval). Conclusion. Our study showed that in many medical institutions where Zafrilla was used for endometriosis both alone and with surgery, clinical improvement was achieved in improving clinical manifestations and significantly reducing the disease recurrence rate. The reduction in endometrioma diameters during non-surgical therapy with Zafrilla without surgery in the study by R. Malik et al. shows the possibilities of modern hormonal drugs and narrows the indications for surgery, allowing the preservation of ovarian reserve along with improving patients' quality of life. Dienogest (Zafrilla) was proven to be effective in pain treatment and prevention of pain recurrence after surgical treatment of endometriosis.

This publication has 12 references indexed in Scilit: